Eli Lilly: A Safe Harbor Amid Market Volatility
Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...
Citi sees positive read-through to Lilly shares on FDA GLP-1 statement
Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
Healio12h
Societies take stand against off-brand GLP-1s over safety concerns
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
Zacks Investment Research on MSN15h
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli ...
Medscape20h
Topical Ruxolitinib Improves Itch, Blistering in Prurigo Nodularis in Study
Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
Ireland’s Profits From Weight-Loss Drugs Draw Trump’s Attention
Irish government mounts a St. Patrick’s Day diplomatic offensive to try and calm Trump anger at ‘massive’ trade surplus.